NCT05202964 Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)
| NCT ID | NCT05202964 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Drug-Related Side Effects and Adverse Reactions |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-06-13 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2024-06-13 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 years * Diagnosis of osteoarticular infection * Treatment with at least one oral antibiotic for a minimum expected duration ≥ 6 weeks with an expected end of treatment date * Patient who was informed and did not object to participate in the study Exclusion Criteria: * Treatment for BJI with oral antibiotic without end of treatment date * treatment for BJI with parenteral antibiotic only * patient who doesn't have a telephone number or who doesn't want to give it * Adults subject to a legal protection measure * Pregnant or breastfeeding women
Contact & Investigator
Valérie MIRABET
PRINCIPAL INVESTIGATOR
Hospices Civils de Lyon
Frequently Asked Questions
Who can join the NCT05202964 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Drug-Related Side Effects and Adverse Reactions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05202964 currently recruiting?
Yes, NCT05202964 is actively recruiting participants. Contact the research team at tristan.ferry@chu-lyon.fr for enrollment information.
Where is the NCT05202964 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT05202964 clinical trial?
NCT05202964 is sponsored by Hospices Civils de Lyon. The principal investigator is Valérie MIRABET at Hospices Civils de Lyon. The trial plans to enroll 60 participants.